Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Gains from Investment Securities (2019 - 2025)

China Pharma Holdings' Gains from Investment Securities history spans 9 years, with the latest figure at -$135320.0 for Q4 2025.

  • For Q4 2025, Gains from Investment Securities fell 101.0% year-over-year to -$135320.0; the TTM value through Dec 2025 reached -$137454.0, down 101.01%, while the annual FY2025 figure was $10000.0, 99.93% down from the prior year.
  • Gains from Investment Securities reached -$135320.0 in Q4 2025 per CPHI's latest filing, down from $13.6 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $13.6 million in Q4 2024 to a low of -$204518.0 in Q3 2023.
  • Average Gains from Investment Securities over 4 years is $2.2 million, with a median of $264.5 recorded in 2021.
  • Peak YoY movement for Gains from Investment Securities: surged 6632.22% in 2024, then plummeted 101.0% in 2025.
  • A 4-year view of Gains from Investment Securities shows it stood at $519.0 in 2021, then surged by 38794.99% to $201865.0 in 2023, then soared by 6632.22% to $13.6 million in 2024, then tumbled by 101.0% to -$135320.0 in 2025.
  • Per Business Quant, the three most recent readings for CPHI's Gains from Investment Securities are -$135320.0 (Q4 2025), $13.6 million (Q4 2024), and $201865.0 (Q4 2023).